Resources Repository
-
ReviewPublication 2005Implications of Modern Decision Science for Military Decision-Support Systems
This review monograph was prepared in response to a request from the United States Air …
This review monograph was prepared in response to a request from the United States Air Force Research Laboratory for a study of modern decision science that would aid in its planning of research programs and, more specifically, developing methods and tools for decision support. The emphasis is on relatively high-level decisionmaking rather than, say, that of pilots or intelligence analysts in the midst of real-time operations. They focus largely on what the military refers to as…
Decision Psychology | Decision Analysis | North America | Decision Theory | Military/Defense -
DataWeb Portal 2024Medical Expenditure Panel Survey (MEPS)
The Medical Expenditure Panel Survey (MEPS) is the only national data source in the U.S. measuring …
The Medical Expenditure Panel Survey (MEPS) is the only national data source in the U.S. measuring how Americans use and pay for medical care, health insurance, and out-of-pocket spending. Annual surveys of individuals and families, as well as their health care providers, provide data on health status, the use of medical services, charges, insurance coverage, and satisfaction with care. The Agency for Healthcare Research and Quality (AHRQ) provides a range of data resources in the form…
Cost-Effectiveness Analysis | Costing Methods | North America | Health Outcomes | Social Determinants | Health Systems | Policy/Regulation | Economics/Finance | Government/Law | Health/Medicine -
ReviewPublication 2015Provider Costs for Cardiovascular Disease in Low-And Middle-Income Countries: A Systematic Review
The burden of cardiovascular disease (CVD) and related conditions is increasing in low- and middle-income countries. Policy …
The burden of cardiovascular disease (CVD) and related conditions is increasing in low- and middle-income countries. Policy makers need an understanding of the magnitude and drivers of the costs of cardiovascular disease related conditions to make decisions on how to allocate limited health resources. This systematic review of the published literature documents provider-incurred costs of treatment for cardiovascular diseases and risk conditions in low- and middle-income countries. Total costs of treatment were inflated to 2012 US dollars for comparability…
Cost-Effectiveness Analysis | Costing Methods | Middle East & North Africa | Chronic Disease/Risk | Health Systems | Economics/Finance | Health/Medicine | Sub-Saharan Africa | Latin America & Caribbean | Asia & Pacific -
ReviewWeb Portal 2015Science of Making Better Decisions About Health: CEA and BCA
This chapter reviews the main scientific methods for guiding the allocation of resources to health: cost-effectiveness …
This chapter reviews the main scientific methods for guiding the allocation of resources to health: cost-effectiveness analysis (CEA) and cost-benefit analysis (CBA), sketches their methodological progress over the last several decades, and presents examples of how medical practice in other high-income countries, where people live longer, follows the priorities indicated by cost-effectiveness analysis.
Benefit-Cost Analysis | Cost-Effectiveness Analysis | North America | Health Systems | Policy/Regulation | Health/Medicine -
ReviewPublication 2013Role of Health Economic Analyses in Vaccine Decision Making
Beginning in the 20th century with the consideration of the seven-valent pneumococcal conjugate vaccine in …
Beginning in the 20th century with the consideration of the seven-valent pneumococcal conjugate vaccine in the US, cost effectiveness became a topic of discussion when a vaccine was being considered for universal use by the US Advisory Committee on Immunization practices (ACIP). In 2008, the ACIP began using formal criteria for the presentation of such data and their inclusion in ACIP discussions. More recently, the U.S. Institute of Medicine has recommended that health economic considerations play a…
Cost-Effectiveness Analysis | North America | Priority Setting/Ethics | Infectious Diseases | Health Systems | Economics/Finance | Health/Medicine -
ReviewPublication 2001Modeling for Health Care and Other Policy Decisions: Uses, Roles and Validity
This is a review article of the role of modeling approaches to guide decision making …
This is a review article of the role of modeling approaches to guide decision making in health care and other domains. The role of models to support recommendations on the cost-effective use of medical technologies and pharmaceuticals is controversial. At the heart of the controversy is the degree to which experimental or other empirical evidence should be required prior to model use. The authors argue that the controversy stems in part from a misconception that…
Technology Assessment | North America | Priority Setting/Ethics | Evidence Synthesis | Mathematical Models | Environmental Health | Health Systems | Policy/Regulation | Business/Industry | Climate/Environment | Economics/Finance | Energy/Engineering | Government/Law | Health/Medicine -
ReviewPublication 2024Cost-Effectiveness of Newer Pharmacologic Treatments in Adults with Type 2 Diabetes: Systematic Review of Cost-Effectiveness Studies for the American College of Physicians
This systematic review examines the cost-effectiveness of newer antidiabetes medications for type 2 diabetes in …
This systematic review examines the cost-effectiveness of newer antidiabetes medications for type 2 diabetes in the United States. The study screened nonindustry-funded cost-effectiveness analyses (CEAs) conducted from 2010 to 2023, focusing on estimating cost per quality-adjusted life-year (QALY) gained. Nine CEAs met the criteria, evaluating medications such as glucagon-like peptide-1 agonists (GLP1a), dipeptidyl peptidase-4 inhibitors (DPP4i), and sodium–glucose cotransporter-2 inhibitors (SGLT2i), among others. Comparisons were made against metformin, sulfonylureas, neutral protamine Hagedorn (NPH) insulin, and…
Cost-Effectiveness Analysis | North America | Chronic Disease/Risk | Health/Medicine -
ReviewPublication 2022Systematic Review of Economic Evaluations of COVID-19 Interventions: Non-Health Impacts and Distributional Issues
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether …
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether they incorporated non-health impacts and distributional concerns. Among the 70 articles included, more than half (56%) included at least one non-health impact, although only 21% incorporated non-economic consequences. Only 17% examined subgroups of interest. The median ICER for the entire sample was $67,000/quality-adjusted life-year (QALY) (interquartile range [IQR] $9000-$893,000/QALY). Interventions including a pharmaceutical component yielded a median ICER of $93,000/QALY (IQR…
Cost-Effectiveness Analysis | North America | Evidence Synthesis | Infectious Diseases | Social Determinants | Culture/Society | Economics/Finance | Health/Medicine -
NewsPublication 2020Online Anti-Vaccine Movement in the Age of COVID-19
This article discusses a recent report by the Centre for Countering Digital Hate (CCDH) that …
This article discusses a recent report by the Centre for Countering Digital Hate (CCDH) that lambasted social media companies for allowing the anti-vaccine movement to remain on their platforms. The CCDH report noted that social media accounts held by so-called anti-vaxxers have increased their following by at least 7-8 million people since 2019. “The decision to continue hosting known misinformation content and actors left online anti-vaxxers ready to pounce on the opportunity presented by coronavirus,”…
North America | Preferences/Values | Infectious Diseases | Social Determinants | Culture/Society | Health/Medicine | Science/Technology